July 27, 2016 11:42 AM ET

Life Sciences Tools and Services

Company Overview of Novella Clinical, Inc.

Company Overview

Novella Clinical, Inc. provides preclinical to post-approval clinical trial management services. Its services include project management, clinical monitoring, data management, data monitoring, investigator strategies and site coordination, safety management, medical monitoring, medical writing, regulatory, quality assurance, steering and clinical advisory, training, and medical device clinical staffing services. The company focuses on various therapeutic areas, including cardiovascular, vascular, gastroenterology, orthopedic, CNS, dermatology, wound care, endocrinology, oncology, and urology. Novella Clinical, Inc. was formerly known as PharmaLinkFHI, Inc. and changed its name to Novella Cli...

1700 Perimeter Park Drive

Morrisville, NC 27560

United States

Founded in 1998





Key Executives for Novella Clinical, Inc.

President and Director
Chief Financial Officer
Age: 58
Chief Operating Officer
Chief Medical Officer
Chief Commercial Officer
Compensation as of Fiscal Year 2016.

Novella Clinical, Inc. Key Developments

ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma

ImmunoCellular Therapeutics, Ltd. announced the establishment of an agreement with Novella Clinical, to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies. The ICT-107 phase 3 trial will include approximately 120 clinical sites in the US, Europe and Canada, and will recruit about 400 patients with newly diagnosed glioblastoma. ImmunoCellular anticipates initiating the phase 3 trial in the fourth quarter of 2015.

Novella Clinical Appoints Deepak Dhami as European Director

Novella Clinical announced the appointment of a director for its European clinical monitoring unit. Pharmafile has reported that Dr. Deepak Dhami has been appointed to the position. With over 20 years of clinical research and operations experience in the pharmaceutical industry, Dr. Dhami has served as functional manager for study management, oncology (pharma development) at Roche, and provided strategic direction on clinical studies for numerous pharma firms in Europe.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

May 1, 2016
BIND Therapeutics, Inc.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novella Clinical, Inc., please visit www.novellaclinical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.